PRONAI NAMES POLYMUN AS PREFERRED MANUFACTURER OF PNT2258
DNAI®-BASED CANCER THERAPEUTIC

Pioneer in DNAi®-based drug development signs manufacturing agreement with Austrian contract biopharmaceutical developer, to help advance lead oncology drug candidate toward IND

Kalamazoo, Michigan and Vienna, Austria – June 14, 2007 – ProNAi Therapeutics, Inc., a biopharmaceutical company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi®), today announced that it has signed a supply agreement with Polymun Scientific GmbH, an Austrian contract biopharmaceutical developer, to manufacture the company’s PNT2258 DNAi®-based cancer therapeutic.

Under the terms of the agreement, Polymun will use its proprietary cross-flow injector technology to manufacture ProNAi’s liposome-formulated lead drug candidate, which is currently in the final stages of preclinical toxicology testing. ProNAi intends to bring PNT2258 to IND submission later this year.

Dr. Richard D. Gill, President and CEO of ProNAi, said, “Polymun has proven, successful experience in manufacturing drug product for U.S. clinical trials, and we are very happy to be working with them as we advance PNT2258 into the clinic. ProNAi is confident that Polymun’s manufacturing processes and technology are state-of-the-art and up to the task of formulating our oncology drug candidate, which features our novel oligo delivery method for the safe and effective administration of nucleic acid-based therapies.”

Dr. Dietmar Katinger, Vice President of Business Development of Polymun, said, “Polymun is delighted to have the opportunity to work with ProNAi in making this innovative drug candidate. Among our specialties, our company has considerable experience in working with liposomal formulations, and we look forward to this fruitful collaboration to help realize the potential oftreating patients with these promisingtherapeutic nucleotides.”

About Polymun Scientific GmbH
Founded in 1992, Polymun Scientific GmbH is a private company offering contract development and production of liposomal formulations as well as development and manufacturing of biopharmaceuticals. Its patented liposome technology allows efficient manufacturing of constantly high quality in small and large scale. Polymun is investing its revenues in its R&D projects and the further development of technology platforms. As a certified manufacturer of pharmaceuticals Polymun operates in accordance with current GLP, GMP and GCP guidelines. Polymun employs a team of about 40 dynamic and highly qualified scientists, technologists and support staff.

Polymun is based in Vienna, Austria. For more information, please visit: www.polymun.com.

About ProNAi Therapeutics, Inc.
ProNAi Therapeutics, Inc. is a biopharmaceutical drug development company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi®), which employs single strands of DNA to target and treat non-transcribed regions of genomes responsible for complex genetic diseases. ProNAi is currently developing multiple DNAi®-based drug candidates with the potential to treat multiple cancers, including non-Hodgkin's lymphoma, prostate, melanoma, breast, and colon cancers. The company’s lead drug candidate, PNT-100, which has demonstrated in vivo efficacy in a variety of human tumor xenograft models, is currently in preclinical development. ProNAi is also exploring the potential of DNAi®-based therapies for indications such as diabetes, Alzheimer’s and inflammatory disease.

ProNAi is based in Kalamazoo, Michigan. For more information, please visit: www.pronai.com.

###